Khaberni - AstraZeneca (AstraZeneca) and Daiichi Sankyo announced stunning results for their new drug "Datroway," which showed great efficacy in extending the life of patients with triple-negative breast cancer, one of the most treatment-resistant types of cancer.
The results were presented during an official showcase at the European Society for Medical Oncology (ESMO) conference, where clinical trials demonstrated that the drug increased the average survival to 23.7 months, compared with only 18.7 months for patients who received conventional chemotherapy.
The data also showed significant improvement in tumor response to the treatment and delayed progression.
How Datroway Works: A "Guided Missile" Towards Cancer Cells
Datroway belongs to the class of Antibody-Drug Conjugates (ADC), an innovative technique that targets cancer cells directly without harming healthy cells.
Doctors liken this technology to guided missiles, where chemotherapy is delivered only to infected cells, reducing toxicity and preserving healthy body tissues.
Susan Galbraith, the Executive Vice President of Oncology Research and Development at AstraZeneca, confirmed that the drug's design allows for "precise and safe delivery of treatment while minimizing complications."
She added that patients who received Datroway stayed on the treatment twice as long compared to those undergoing chemotherapy, with similar rates of side effects and fewer withdrawals from the trial.
Abd al-‘Ladem, head of clinical development at Daiichi Sankyo, explained that this trial "is the first to demonstrate the superiority of a new treatment like Datroway over standard treatment in terms of survival."
The results represent a turning point in the treatment of aggressive breast cancer, confirming the potential of relying on such advanced treatments as a safer and more effective alternative to traditional chemotherapy.
Early US Approval and Preparation for Global Competition
Earlier this year, the US Food and Drug Administration (FDA) granted its approval for the use of Datroway to treat specific types of breast and lung cancer, thus enhancing the drug's global standing as one of the latest innovations in solid tumor treatment.
Ken Keller, head of the oncology unit at Daiichi Sankyo, said that the company expects Datroway to outperform its competitors, particularly Gilead's drug "Trodelvy," thanks to its high efficacy and ease of use, as it is given only every two weeks.
Datroway is expected to change the global oncology drug market landscape, especially in light of the increasing shift towards targeted and safe treatments. With ongoing clinical trials, the drug could become a main choice in treatment protocols for aggressive breast cancer in the coming years.
